A Post Marketing Surveillance Study on the Safety and Effectiveness of Prucalopride in the Treatment of Chronic Constipation
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01692132 |
|
Recruitment Status :
Withdrawn
(The company decided to cancel this study in conformity with PH FDA Circular 2013-004)
First Posted : September 25, 2012
Last Update Posted : December 2, 2015
|
Sponsor:
Janssen Pharmaceutica
Information provided by (Responsible Party):
Janssen Pharmaceutica
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The purpose of this study is to determine the safety and effectiveness of prucalopride in the treatment of Filipino patients with chronic constipation whom prior laxatives fail to provide adequate relief.
| Condition or disease | Intervention/treatment |
|---|---|
| Chronic Constipation | Drug: Prucalopride |
This is a 12-week open label (all people know the identity of the intervention), multi-center, prospective (the patients are identified and then followed forward in time for the outcome of the study) observational study assessing the safety and effectiveness of prucalopride among Filipino patients with chronic constipation. Chronic constipation is a condition in which bowel movements are infrequent or incomplete for a prolonged time. The use of prucalopride should be used in accordance with the approved product label and will follow the normal medical practice of the investigators. Patients should take 2 mg prucalopride tablet orally once daily. For elderly patients (>65 years old), patients with renal impairment not requiring dialysis or patients with severe hepatic impairment, 1mg prucalopride once daily should be given. Patients will be asked to fill-up a patient diary daily for 12-weeks to monitor the bowel movement during the study period. All adverse events and concomitant medications taken by the patients during the study will be documented accordingly. Patients will be monitored during the 12-week period of observation while the patients are in prucalopride treatment.
| Study Type : | Observational |
| Actual Enrollment : | 0 participants |
| Observational Model: | Cohort |
| Time Perspective: | Prospective |
| Official Title: | A Study on the Safety and Effectiveness of Prucalopride in the Treatment of Chronic Constipation |
| Study Start Date : | February 2013 |
| Estimated Primary Completion Date : | February 2014 |
| Estimated Study Completion Date : | December 2014 |
Resource links provided by the National Library of Medicine
MedlinePlus related topics:
Constipation
| Group/Cohort | Intervention/treatment |
|---|---|
| Prucalopride |
Drug: Prucalopride
Prucalopride 2 mg tablet/day orally for 12 weeks. For elderly patients (>65 years old), patients with renal impairment not requiring dialysis or patients with severe hepatic impairment, 1mg prucalopride once daily should be given. |
Primary Outcome Measures :
- The incidence of patients discontinuing treatment due to adverse events, serious adverse events, or adverse drug reactions [ Time Frame: 12 weeks ]
Secondary Outcome Measures :
- The percentage of patients having at least 3 spontaneous complete bowel movements (SCBM) in a week after treatment with prucalopride [ Time Frame: 12 weeks ]SCBM is defined as a sense of complete evacuation of bowel without straining.
- The change from baseline in the Patient Assessment of Constipation Symptoms (PAC-SYM) score after treatment with prucalopride [ Time Frame: Baseline, 12 weeks ]The PAC-SYM questionnaire is a 12-item survey that measures constipation symptoms and associated severity across three domains: stool symptoms, rectal symptoms, and abdominal symptoms. Symptom items are rated on a 5-point Likert severity scale. Item values are scored from 0 to 4, with 0 indicating absence of symptom, 1 = mild, 2 = moderate, 3 = severe, and 4 = very severe indicating the worst severity of that symptom.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
Filipino patients with chronic constipation
Criteria
Inclusion Criteria:
- Diagnosis of chronic constipation by history and physical examination, including rectal exam
- History of chronic constipation not satisfied with laxatives
- Patient reports, on average, 2 or fewer spontaneous bowel movements (SBMs) per week and 1 or more of the following for the last three months: very hard (little balls) and/or hard stools in more than 25% of bowel movements (BMs); sensation of incomplete evacuation in more than 25% of BMs; straining at defecation in more than 25% of BMs; sensation of ano-rectal obstruction or blockade in more than 25% of BMs; a need for digital manipulation to facilitate evacuation in more than 25% of BMs
- Females of childbearing potential agree to use highly effective contraceptive methods
Exclusion Criteria:
- Renal impairment requiring dialysis
- Secondary chronic constipation and organic gastrointestinal (GI) disorders
- Intestinal perforation / obstruction due to structural or functional disorder of the gut wall, obstructive ileus, severe inflammatory condition of the intestinal tract such as Crohn's disease, ulcerative colitis, toxic megacolon / rectum
- Hypersensitive to Prucalopride or to any of its components
- Patients receiving concomitant drugs known to cause QTc prolongation
- Pregnant or lactating
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01692132
Locations
| Philippines | |
| Makati City, Philippines | |
| Manila, Philippines | |
| Marikina City, Philippines | |
| Muntinlupa, Philippines | |
| Quezon City, Philippines | |
| San Juan, Philippines | |
| Taguig, Philippines | |
Sponsors and Collaborators
Janssen Pharmaceutica
Investigators
| Study Director: | Janssen Pharmaceutica Clinical Trial | Janssen Pharmaceutica |
| Responsible Party: | Janssen Pharmaceutica |
| ClinicalTrials.gov Identifier: | NCT01692132 History of Changes |
| Other Study ID Numbers: |
CR017521 PRUCOP4001 ( Other Identifier: Janssen Pharmaceutica ) |
| First Posted: | September 25, 2012 Key Record Dates |
| Last Update Posted: | December 2, 2015 |
| Last Verified: | November 2015 |
Keywords provided by Janssen Pharmaceutica:
|
Chronic Constipation Prucalopride Post Marketing Surveillance |
Additional relevant MeSH terms:
|
Constipation Signs and Symptoms, Digestive Signs and Symptoms |